ONC Share Price

Open 0.29 Change Price %
High 0.29 1 Day 0.00 0.00
Low 0.28 1 Week 0.00 0.00
Close 0.28 1 Month 0.00 0.00
Volume 146000 1 Year -0.09 -24.32
52 Week High 0.75
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.29
Resistance 1 0.29
Pivot 0.28
Support 1 0.27
Support 2 0.27
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
BBD-B 2.51 -3.83%
ORT 0.34 30.77%
ORT 0.34 30.77%
TBE 0.03 0.00%
IVN 3.94 6.78%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
ORT 0.34 30.77%
ORT 0.34 30.77%
BOX-UN 31.01 18.31%
RVX 2.00 17.65%
CUM 0.90 13.92%
CUM 0.90 13.92%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
MM 0.06 -14.29%
MM 0.06 -14.29%
HYG 6.56 -9.64%
CTU-A 0.19 -9.52%
CXA-B 1.00 -9.09%
CCZ 0.13 -7.14%
DEJ 0.14 -6.67%
DEJ 0.14 -6.67%
FTG 4.43 -6.54%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 2
As on 23rd Jan 2017 ONC Share Price closed @ 0.28 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.40 & Buy for SHORT-TERM with Stoploss of 0.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.